BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 25209551)

  • 1. Novel radiotherapy techniques for involved-field and involved-node treatment of mediastinal Hodgkin lymphoma: when should they be considered and which questions remain open?
    Lohr F; Georg D; Cozzi L; Eich HT; Weber DC; Koeck J; Knäusl B; Dieckmann K; Abo-Madyan Y; Fiandra C; Mueller RP; Engert A; Ricardi U
    Strahlenther Onkol; 2014 Oct; 190(10):864-6, 868-71. PubMed ID: 25209551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiotherapy for early mediastinal Hodgkin lymphoma according to the German Hodgkin Study Group (GHSG): the roles of intensity-modulated radiotherapy and involved-node radiotherapy.
    Koeck J; Abo-Madyan Y; Lohr F; Stieler F; Kriz J; Mueller RP; Wenz F; Eich HT
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):268-76. PubMed ID: 22079733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different IMRT solutions vs. 3D-conformal radiotherapy in early stage Hodgkin's Lymphoma: dosimetric comparison and clinical considerations.
    Fiandra C; Filippi AR; Catuzzo P; Botticella A; Ciammella P; Franco P; Borca VC; Ragona R; Tofani S; Ricardi U
    Radiat Oncol; 2012 Nov; 7():186. PubMed ID: 23122028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consolidative involved-node proton therapy for Stage IA-IIIB mediastinal Hodgkin lymphoma: preliminary dosimetric outcomes from a Phase II study.
    Hoppe BS; Flampouri S; Su Z; Morris CG; Latif N; Dang NH; Lynch J; Li Z; Mendenhall NP
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):260-7. PubMed ID: 22014950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involved-node and involved-field volumetric modulated arc vs. fixed beam intensity-modulated radiotherapy for female patients with early-stage supra-diaphragmatic Hodgkin lymphoma: a comparative planning study.
    Weber DC; Peguret N; Dipasquale G; Cozzi L
    Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1578-86. PubMed ID: 19596171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG).
    Specht L; Yahalom J; Illidge T; Berthelsen AK; Constine LS; Eich HT; Girinsky T; Hoppe RT; Mauch P; Mikhaeel NG; Ng A;
    Int J Radiat Oncol Biol Phys; 2014 Jul; 89(4):854-62. PubMed ID: 23790512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case study evaluating deep inspiration breath-hold and intensity-modulated radiotherapy to minimise long-term toxicity in a young patient with bulky mediastinal Hodgkin lymphoma.
    Tomaszewski JM; Crook S; Wan K; Scott L; Foroudi F
    J Med Radiat Sci; 2017 Mar; 64(1):69-75. PubMed ID: 28188697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimising critical organ irradiation in limited stage Hodgkin lymphoma: a dosimetric study of the benefit of involved node radiotherapy.
    Campbell BA; Hornby C; Cunninghame J; Burns M; MacManus M; Ryan G; Lau E; Seymour JF; Wirth A
    Ann Oncol; 2012 May; 23(5):1259-1266. PubMed ID: 21980193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicted risk of radiation-induced cancers after involved field and involved node radiotherapy with or without intensity modulation for early-stage hodgkin lymphoma in female patients.
    Weber DC; Johanson S; Peguret N; Cozzi L; Olsen DR
    Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):490-7. PubMed ID: 20800383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma.
    Maraldo MV; Brodin NP; Aznar MC; Vogelius IR; Munck af Rosenschöld P; Petersen PM; Specht L
    Ann Oncol; 2013 Aug; 24(8):2113-8. PubMed ID: 23619032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involved Node, Site, Field and Residual Volume Radiotherapy for Lymphoma: A Comparison of Organ at Risk Dosimetry and Second Malignancy Risks.
    Murray L; Sethugavalar B; Robertshaw H; Bayman E; Thomas E; Gilson D; Prestwich RJ
    Clin Oncol (R Coll Radiol); 2015 Jul; 27(7):401-10. PubMed ID: 25840609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative treatment planning study for mediastinal Hodgkin's lymphoma: impact on normal tissue dose using deep inspiration breath hold proton and photon therapy.
    Edvardsson A; Kügele M; Alkner S; Enmark M; Nilsson J; Kristensen I; Kjellén E; Engelholm S; Ceberg S
    Acta Oncol; 2019 Jan; 58(1):95-104. PubMed ID: 30280626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma.
    Hoppe BS; Flampouri S; Su Z; Latif N; Dang NH; Lynch J; Joyce M; Sandler E; Li Z; Mendenhall NP
    Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):449-55. PubMed ID: 22386373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical relevance of different dose calculation strategies for mediastinal IMRT in Hodgkin's disease.
    Koeck J; Abo-Madyan Y; Eich HT; Stieler F; Fleckenstein J; Kriz J; Mueller RP; Wenz F; Lohr F
    Strahlenther Onkol; 2012 Aug; 188(8):653-9. PubMed ID: 22740169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involved-nodal radiation therapy leads to lower doses to critical organs-at-risk compared to involved-field radiation therapy.
    Mulvihill DJ; McMichael K; Goyal S; Drachtman R; Weiss A; Khan AJ
    Radiother Oncol; 2014 Aug; 112(2):279-83. PubMed ID: 25082095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fondazione Italiana Linfomi (FIL) expert consensus on the use of intensity-modulated and image-guided radiotherapy for Hodgkin's lymphoma involving the mediastinum.
    Filippi AR; Meregalli S; DI Russo A; Levis M; Ciammella P; Buglione M; Guerini AE; De Marco G; De Sanctis V; Vagge S; Ricardi U; Simontacchi G;
    Radiat Oncol; 2020 Mar; 15(1):62. PubMed ID: 32164700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimizing late effects for patients with mediastinal Hodgkin lymphoma: deep inspiration breath-hold, IMRT, or both?
    Aznar MC; Maraldo MV; Schut DA; Lundemann M; Brodin NP; Vogelius IR; Berthelsen AK; Specht L; Petersen PM
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):169-74. PubMed ID: 25754634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of radiation techniques in the treatment of mediastinal lymphoma: from 3D conformal radiotherapy (3DCRT) to intensity-modulated RT (IMRT) using helical tomotherapy (HT): a single-centre experience and review of the literature.
    Besson N; Pernin V; Zefkili S; Kirova YM
    Br J Radiol; 2016; 89(1059):20150409. PubMed ID: 26744079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involved-site image-guided intensity modulated versus 3D conformal radiation therapy in early stage supradiaphragmatic Hodgkin lymphoma.
    Filippi AR; Ciammella P; Piva C; Ragona R; Botto B; Gavarotti P; Merli F; Vitolo U; Iotti C; Ricardi U
    Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):370-5. PubMed ID: 24613810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of passive-beam proton therapy, helical tomotherapy and 3D conformal radiation therapy in Hodgkin's lymphoma female patients receiving involved-field or involved site radiation therapy.
    Horn S; Fournier-Bidoz N; Pernin V; Peurien D; Vaillant M; Dendale R; Fourquet A; Kirova YM
    Cancer Radiother; 2016 Apr; 20(2):98-103. PubMed ID: 26992750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.